Canada's Cosciens Biopharma Q3 loss widens on impairment and acquisition costs
Canada's Cosciens Biopharma Q3 loss widens on impairment and acquisition costs Overview Canadian pha
Related stories
Centrica and Equinor Advance to Next Round of Uniper Sale
Centrica and Equinor are in the next round of Germany’s Uniper sale, Bloomberg News reports.
M impact | MNA | Nov 14, 2026, 10:23 AM UTC
Pricol Promoters to Sell 38.51% Stake in Autotech Unit to Warburg Pincus
Pricol said its board approved the sale of promoters’ entire 38.51% shareholding in Pricol Autotech Limited to Warburg Pincus.
M impact | MNA | Nov 14, 2026, 02:29 AM UTC
High Arctic Energy Services Agrees to Go-Private Sale to Newport Capital
High Arctic Energy Services entered into a definitive acquisition agreement and announced its intent to make a cash distribution to shareholders.
M impact | MNA | Nov 14, 2026, 01:01 AM UTC
Hall Chadwick Acquisition Sets Shareholder Vote on REEcycle Merger
Hall Chadwick Acquisition announced a shareholder meeting to vote on its merger with REEcycle.
M impact | MNA | Nov 13, 2026, 09:49 PM UTC
Surgery Partners Raises HealthSpan Merger Price to $25 per Share
Surgery Partners raised its merger price for HealthSpan to $25 per share after a competing bid.
M impact | MNA | Nov 13, 2026, 05:53 PM UTC
GCI Completes Quintillion Acquisition to Consolidate Alaska Fibre Networks
GCI completed its acquisition of Quintillion, consolidating Alaska fibre networks.
M impact | MNA | Nov 13, 2026, 05:53 PM UTC